Tirzepatide and NAD+ Together: What Is Known
Tirzepatide and NAD+ taken together: what each one is, how each is regulated, and what is known about combining them.
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Coenzyme (injectable, IV or nasal)CompoundedNAD+Coenzyme sold as an injectable wellness product; a systematic review concluded clinical effectiveness for anti-aging or wellness outcomes remains inconclusive.[11]
Interaction notes
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 3 results, 2 Oct 2026).
NAD+ is not FDA approved, and we have no sourced data on combining it with Tirzepatide.
Each component
Side by side
Showing 9 of 10 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.
| Field | Tirzepatide | NAD+ |
|---|---|---|
| Class | GLP-1 / GIP dual agonist | Coenzyme (injectable, IV or nasal) |
| Also called | tirz, tirze, Mounjaro, Zepbound | NAD, nicotinamide adenine dinucleotide |
| FDA status | FDA approved (Mounjaro, Zepbound) | Compounded |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. | No WADA record in our data |
| Half-life | approximately 5 dayssubcutaneous · FDA label (Mounjaro) | [half-life by route] |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 | [evidence grade] |
| Human studies we summarised | 24 human (22 randomized or controlled) of 30 summarised | [n] |
| Typical study doses |
| [dose range] |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026; 31 Mar 2026) | Not in the letters we track |
What people search
- tirzepatide with nad260/mo
- tirzepatide nad170/mo
- nad with tirzepatide110/mo
- nad and tirzepatide110/mo
- tirzepatide and nad90/mo
- nad and tirzepatide together70/mo
US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 7Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 8Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 9PubMed search: ("NAD+"[tiab] OR "nicotinamide adenine dinucleotide"[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 11NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.Ageing research reviews · 2026PMID 41655607Accessed 2 Oct 2026
Found an error? Report a correction.